Pharmacokinetics and pharmacodynamics of recombinant human interferon- β in healthy male volunteers

Journal of Interferon and Cytokine Research

Volumn 16, Issue 10, 1996, Pages 759-764

  Salmon, P ^a   Le Cotonnec, J Y ^b   Galazka, A ^c   Abdul Ahad, A ^c   Darragh, A ^d  

^a National Drugs Advisory Board   (Ireland)

^b Triskel Biomedical Consulting   (Switzerland)

^c Serono International SA   (Switzerland)

^d Pain Care Clinic   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; RECOMBINANT BETA INTERFERON;

ADULT; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; INFLUENZA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA;

EID: 0029912760     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.759     Document Type: Article

References (20)

1. PESTKA, S., LANGER, J.A., ZOON, K.C., and SAMUEL, C.E. (1987). IFNs and their actions. Annu. Rev. Biochem. 56, 727-772.
2. REVEL, M., and CHEBATH, J. (1986). Interferon-activated genes. Trends Biochem. Sci. 11, 166-170.
3. SCHONFELD, A., SCHATTNER, A., CRESPI, M., LEVATI, H., SHOHAM, J., NITKE, S., WALLACH, D., HAHN, T., YARDEN, O., DOERNER, T., and REVEL, M. (1984). Intramuscular human interferon-β injections in treatment of condylomata acuminata. Lancet 23, 1038-1041.
4. SPEAR, G.T., PAULNOCK, D.M., JORDAN, R.L., MELTZER, D.M., MERRITT, J.A., and BORDEN, E.C. (1987). Enhancement of monocyte class I and II histocompatibility antigen expression in many by in vivo beta-interferon. Clin. Exp. Immunol. 69, 107-115.
5. BORDEN, E.C., HAWKINS, M.J., SIELAFF, K.M., STORER, B.M., SCHIESEL, J.D., and SMALLEY, R.B. (1988). Clinical and biological effects of recombinant interferon beta administered intravenously daily in a phase I trial. J. Interferon Res. 8, 357-366.
6. LIBERATI, A.M., FIZZOTTI, M., PROIETTI, M.G., DI MARZIO, R., SHIPPA, M., BISCOTTINI, B., SENATORE, M., BERRUTO, P., CANALI, S., PERETTI, G., and ZANOLO, G. (1988). Biochemical host response to interferon-β. J. Interferon Res. 8, 765-777.
7. GOLDSTEIN, D., SIELAFF, K.M., STORER, B.E., BROWN, R.R., DATTA, S.P., WITT, P.L., TEITELBAUM, A.P., SMALLEY, R.V., and BORDEN, E.C. (1989). Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J. Natl. Cancer Inst. 81, 1061-1068.
8. BORDEN, E.C., RINEHART, J.J., STORER, B.E., TRUMP, D.L., PAULNOCK, D.M., and TEITELBAUM, A.P. (1990). Biological and clinical effects of interferon betaser at two doses. J. Interferon Res. 10, 559-570.
9. WITT, P.L., SPEAR, G.T., HELGESON, D.O., LINDSTROM, M.J., SMALLEY, R.V., and BORDEN, E.C. (1990). Basal and interferon-induced 2′5′-oligoadenylate synthetase in human monocytes, lymphocytes and peritoneal macrophages. J. Interferon Res. 10, 393-402.
10. SCHILLER, J.H., STORER, B., WILT, P.L., NELSON, B., BROWN, R.R., HORISBERGER, M., GROSSBERG, S., and BORDEN, E.C. (1990). Biological and clinical effects of the combination of β- and γ-interferons administered as a 5-day continuous infusion. Cancer Res. 50, 4588-4594.
11. LIBERATI, A.M., HORISBERGER, M., SCHIPPA, M., DI CLEMENTE, F., FIZZOTTI, M., FILIPPO, S., PROIETTI, M.G., ARZANO, S., BERRUTO, P., PALMISANO, L., and CLINIERI, S. (1991). Biochemical and immunological responses of hairy cell leukemia patients to interferon-β. Cancer Immunol. Immunother. 34, 115-122.
12. LIBERATI, A.M., HORISBERGER, M.A., PALMISANO, L., ASTOLFI, S., NASTARI, A., MECHATI, S., VILLA, A., MANCINI, S., ARZANO, S., and GRIGNANI, F. (1992). Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J. Interferon Res. 12, 329-336.
13. WITT, P.L., STORER, B.E., BRYAN, G.T., BROWN, R.R., FLASHNER, M., LAROCCA, A.T., COLBY, C.B., and BORDEN, E.C. (1993). Pharmacodynamics of biological response in vivo after multiple doses of interferon-β. J. Immunother. 13, 191-200.
14. CHIANG, J., GLOFF, C., YOSHIZAWA, C., and WILLIAMS, G. (1993). Pharmacokinetics of recombinant human interferon-βser in healthy volunteers and its effect on serum neopterin. Pharmaceut. Res. 10, 567-572.
15. LIBERATI, A., GAROFANI, P., DE ANGELIS, V., et al. (1994). Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J. Interferon Res. 14, 61-69.
16. GIBALDI, M., and PERRIER, D. (1982). Pharmacokinetics, 2nd ed. New York: Marcel Dekker Inc.
17. BOCCI, V. (1988). The lympathic route. V. Distribution of human natural interferon-β in rabbit plasma and lymph. J. Interferon Res. 8, 633-640.
18. JACOBS, L., and MUNSCHAUER, F. (1992). Treatment of multiple sclerosis with interferons. In: R. Rudick, and D. Goodkin (eds.) Multiple Sclerosis, Trial Design, Results and Future Perspectives. Springer-Verlag, pp. 233-250.
19. McDONALD, S., CHANG, A.Y., RUBIN, P., WALLENBERG, J., KIM, I.S., SOBER, S., SMITH, J., KENG, P., and MUHS, A. (1993). Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 27, 613-619.
20. NAGASHIMA, H., ARIMA, T., and SUZUKI, H. (1987). Treatment of chronic non-A, non-B hepatitis with human interferon-beta. J. Med. Virol. 21, 128A.